John Hayes
Psychiatric/Mental Health · Mobile, ALNPI 1023285228
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,550 of the $29,636 with a category attached, or 62.6%. Alkermes, Inc. accounts for 90.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $19,742 and has fallen 99.9% since, to $15 in 2025. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $127.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$27K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$833
- Otsuka America Pharmaceutical, Inc.$766
- Neurocrine Biosciences, Inc.$320
- Johnson & Johnson$315
- AbbVie$238
- plus $363 from 9 others
What the payments were for
- Consulting fees$3,05010%
- Speaking & faculty fees$18,55063%
- Travel & lodging$3,21211%
- Food & beverage$4,77316%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 58 | $26,801 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $833 |
| Otsuka America Pharmaceutical, Inc. | 50 | $766 |
| Neurocrine Biosciences, Inc. | 17 | $320 |
| Johnson & Johnson | 21 | $315 |
| AbbVie | 20 | $238 |
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 4 | $56 |
| Indivior Inc. | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Corium, LLC | 2 | $35 |
| Lundbeck LLC | 1 | $19 |
| Bausch Health US, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$60,643
- ARISTADA$47,984
- ARISTADA INITIO$6,505
How this compares
$29,636 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $229,484 |
| Invega SustennaPaliperidone Palmitate | 39 | $95,917 |
| Abilify MaintenaAripiprazole | 26 | $71,716 |
| AristadaAripiprazole Lauroxil | 11 | $35,350 |
| VraylarCariprazine Hcl | 21 | $29,363 |
| Risperdal ConstaRisperidone Microspheres | 13 | $24,012 |
| TrintellixVortioxetine Hydrobromide | 42 | $20,175 |
| Lurasidone Hcl | 39 | $6,642 |
| Aripiprazole | 36 | $5,100 |
| Asenapine Maleate | 13 | $3,960 |
| Quetiapine Fumarate | 106 | $2,247 |
| Olanzapine OdtOlanzapine | 31 | $1,940 |
| Olanzapine | 48 | $1,884 |
| Atomoxetine Hcl | 12 | $1,701 |
| Divalproex Sodium ErDivalproex Sodium | 54 | $1,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $320 | $229,48429 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $315 | $119,92952 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $766 | $71,71626 claims |
| Alkermes, Inc.Aristada | $26,801 | $35,35011 claims |
| AbbVieVraylar | $238 | $29,36321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $20,17542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Mobile
- Tammy LeeMobile$12K
- Mary LeeMobile$11K
- Robert WillettMobile$10K
- Dolores BrayMobile$9K
- Beverly AlesMobile$7K
- Kina HooksMobile$7K
- Wanda WhiddonMobile$6K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.